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BACKGROUND: The purpose of this study was to identify factors associated with colorectal cancer (CRC) screening test
preference and examine the association between test preference and test completed. METHODS: Patients (n¼ 1224)
were 50-70 years, at average CRC risk, and overdue for screening. Outcome variables were preference for fecal
occult blood test (FOBT), colonoscopy (COL), sigmoidoscopy (SIG), or barium enema (BE), measured by telephone
survey, and concordance between test preference and test completed assessed using medical records. RESULTS:
Thirty-five percent preferred FOBT, 41.1% COL, 12.7% SIG, and 5.7% BE. Preference for SIG or COL was associated with
having a physician recommendation, greater screening readiness, test-specific self-efficacy, greater CRC worry, and per-
ceived pros of screening. Preference for FOBT was associated with self-efficacy for doing FOBT. Participants who pre-
ferred COL were more likely to complete COL compared with those who preferred another test. Of those screened, only
50% received their preferred test. Those not receiving their preferred test most often received COL (52%). CONCLU-
SIONS: Lack of concordance between patient preference and test completed suggests that patients’ preferences are
not well incorporated into screening discussions and test decisions, which could contribute to low screening uptake.
Physicians should acknowledge patients’ preferences when discussing test options and making recommendations, which
may increase patients’ receptivity to screening. Cancer 2012; 118:2726–34. VC 2011 American Cancer Society.
KEYWORDS: colorectal cancer, screening, patient education, decision making.
Recommendations from the 2010 National Institute of Health State of the Science Conference, ‘‘Enhancing
Use and Quality of Colorectal Cancer Screening,’’ state there is a need to better understand the association between
patients’ preferences and the use of colorectal cancer (CRC) screening tests.1 This recommendation stems largely from the
finding that national organizations endorse multiple options for the early detection and prevention of CRC.2,3 The most
commonly recommended modalities include the fecal occult blood test (FOBT), fecal immunochemical test (FIT), and
colonoscopy (COL), but other tests, including flexible sigmoidoscopy (SIG), double-contrast barium enema (BE), and
virtual colonoscopy (V-COL), are also considered options for screening. Although CRC screening rates have gradually
increased over the past 10 years, they remain lower than those for other cancers.4,5 Incorporating patients’ preferences into
physicians’ screening recommendations may be a way to increase screening rates.
A number of studies have described variation in patients’ preferences for CRC screening tests,6-15 and some have
examined sociodemographic characteristics associated with preferences.8,9,11-16 Studies are consistent in reporting that
stool blood testing and endoscopy (usually COL) are most often cited as the preferred options. With a few exceptions,7,13
studies also have been consistent in reporting that sociodemographic characteristics including age, sex, race/ethnicity, and
education are not associated with test preferences.9,11,12,14-16
Associations between test preferences and test characteristics such as accuracy, convenience, and discomfort have also
been examined.6-9,11,13-16 Concern about discomfort and convenience was consistently associated with a preference for
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FOBT,6-9,11,13,14 whereas test accuracy was consistently
associated with a preference for SIG or COL.7,8,11,13-16
Screening-related factors such as physician recommendation
and prior screening also have been examined in relation to
test preferences, but results have been inconsistent.6,8-13,16
With the exception of Powell et al,12 very few studies
have examined the associations between test preference
and psychosocial factors such as perceived risk and self-
efficacy, and most of the others examined only 1 or 2 con-
structs.6,8,9,16 Only 3 studies have examined the relation
between CRC screening test preference and the CRC test
completed15,17 or ordered by a physician.14 Wolf et al15
found that approximately 40% of their study sample did
not receive the test they said they preferred, and Ruffin
et al17 found only modest correlations between preferred
test and test received. Although Schroy et al14 did not
examine completion of screening, they found that 40% of
the time physicians did not order the test their patient
preferred.
Because psychosocial factors may influence CRC
screening test preferences, which, in turn, may influence
uptake of CRC screening, we examined the associations
between a number of psychosocial variables and CRC test
preference. We also assessed the concordance between
baseline CRC screening test preference and the type of
test completed.
MATERIALS AND METHODS
Data from these analyses are from a 5-year randomized
behavioral intervention trial designed to increase CRC
screening.18 The trial was approved by the institutional
review board at the University of Texas School of Public
Health (UTSPH) and is registered on clinicaltrials.gov
(NCT01084746).
Selection and Recruitment of Study
Population
The study was conducted at Kelsey-Seybold Clinic, the
largest multispecialty medical organization in Houston,
Texas, with 21 locations. Eligible patients had received
primary care at the clinic within the past year, were
between 50 and 70 years old, never had CRC or polyps,
had never been screened or were due for CRC screening
according to American Cancer Society guidelines in effect
at the time of the study,19 had not had a physical exam
within the past year, did not have a prior diagnosis of
Crohn’s disease or ulcerative colitis, and were able to
speak English.
Between January 2004 and February 2006, staff at
the Kelsey Research Foundation mailed invitation letters
to potentially eligible patients, who were identified
monthly from the clinic’s administrative database. A con-
tact telephone number was included in the letter so that
recipients could call and decline participation. Staff at the
foundation telephoned patients who did not decline to
introduce the study, confirm eligibility, and enroll them.
Invitees were considered nonrespondents if they could not
be reached after 6 calls that were made during different
times of the day and on different days of the week. Con-
tact information for interested patients was sent to the
UTSPH research staff members, who conducted baseline
telephone surveys. Of 1384 patients enrolled by founda-
tion staff, 1224 (88%) completed a baseline survey; this
group constituted the analysis sample for this study. A
detailed description of the process of recruitment and
enrollment, including a CONSORT diagram, was pub-
lished elsewhere.18
Data Collection and Study Design
After administration of the baseline survey, participants
were randomized to 1 of 3 study groups stratified by sex
and past CRC screening status (ever screened vs overdue
for screening). The tailored intervention group partici-
pated in an interactive, tailored computer program; the
Web site group viewed general information about CRC
screening from a publicly available Web site, Screen for
Life, which is the national CRC awareness campaign from
the Centers for Disease Control and Prevention; and the
survey-only control group received no additional
information about CRC screening. As part of the study,
all participants completed a wellness visit and exam. At
the 12-month follow-up, medical records were reviewed
to collect CRC screening utilization data. Additional
details on the intervention trial and outcome results,
including factors associated with CRC screening adher-
ence, were reported elsewhere.18
Measures
Outcome variables
The outcome used to examine correlates of CRC
test preference was self-reported CRC screening test pref-
erence as measured on the baseline survey. Respondents
were asked: ‘‘Now that you have heard descriptions of all 4
colon cancer screening tests, which one would you prefer to
get, if you had a choice?’’ Responses included FOBT, SIG,
COL, BE, and don’t know/not sure.
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The other outcome was concordance between test
preference at baseline and type of CRC test received
(FOBT, SIG, COL, BE) 12 months post intervention.
Test received was ascertained from the clinic’s medical
record and administrative databases. For patients who
completed more than 1 screening test during the study
period, we counted the first test completed.
Correlates
Because there is scant research on the psychosocial
correlates of CRC test preferences, we selected variables
from the baseline survey that have been shown in the liter-
ature to be associated with CRC screening.20,21 Patient
characteristics and the categories used for analytic
purposes were: age (continuous), race (white, African
American, Hispanic/other), sex (male/female), marital
status (married/partnered, not married/divorced/wid-
owed), employment status (employed, not employed/
retired/disabled), education (high school graduate or less,
some college, college graduate, postcollege education),
and family history of CRC (yes, no). All participants in
this study were insured; therefore, we did not include
insurance status as a patient characteristic.18
Screening-related factors included prior CRC
screening (yes or no), type of test received (FOBT, SIG,
COL, BE), physician recommendation, stage of change or
readiness to be screened, and preference for involvement
in medical decision making. Prior screening was assessed
with a standard set of measures.22 Patients were asked if
they had ever received a physician’s recommendation to
be screened for CRC (yes or no) as well as whether they
received a test-specific recommendation for FOBT, SIG,
COL, or BE. Stage of readiness to get CRC screening was
measured as precontemplation (not thinking about test-
ing), contemplation, or preparation for action (commit-
ted to getting tested). Contemplation was measured using
3 questions: need to consider testing, think I should but
am not quite ready, and think I will probably get tested.
We used the 5-point Control Preferences Scale23 to char-
acterize respondents’ beliefs about how medical decisions
should be made. We collapsed the scale into 3 categories
reflecting a preference for a patient-based, shared, or phy-
sician-based decision.7,24 Participants who did not
respond to this question were coded as having an
unknown preference.
Psychosocial factors included participants’ test-
specific self-efficacy, comparative perceived risk, worry
about CRC, CRC knowledge, and perceived pros and
cons of CRC screening. Test-specific self-efficacy was
assessed with 4 items reflecting the degree to which
respondents felt confident in completing each test
(FOBT, SIG, COL, BE). The 4 response categories were
dichotomized for analysis (very confident, confident, not
very confident, not at all confident). Comparative per-
ceived risk was measured with a single item from the 2003
Health Information and National Trends Survey (less
likely, equally likely, or more likely to develop CRC com-
pared with others my age). Worry about CRC was meas-
ured with a single item (never, rarely, sometimes, most of
the time, all of the time). Knowledge was measured with 4
items (true/false). Perceived pros (a¼ 0.75, items¼ 8)
and cons (a¼ 0.78, items¼ 10) for getting CRC screen-
ing were measured using validated multi-item scales with
a 4-point response scale ranging from ‘‘not very impor-
tant’’ to ‘‘very important.’’25 We calculated mean scores
for knowledge as well as perceived pros and cons of CRC
screening.
Data Analysis
Univariable associations between baseline CRC test pref-
erence (FOBT, COL, SIG, or BE) and categorical inde-
pendent variables were analyzed using chi-square
contingency tables; continuous variables were analyzed
using t tests and 1-way analysis of variance. Variables that
were associated with test preference in univariable analyses
at P< .10 were included in multivariable analyses to iden-
tify factors independently associated with preference
stated at baseline. As recommended by Hosmer and
Lemeshow, we used a less conservative P value (P < .10)
to select variables for inclusion in the multivariable analy-
ses in order to reduce the possibility we would exclude var-
iables that could be important.26 We then performed a
multinomial analysis using 3 outcome variables: FOBT,
SIG, and COL. We used FOBT as the referent category
to compare COL versus FOBT and SIG versus FOBT.
We then used SIG as the referent category to compare
COL versus SIG. Results were summarized with odds
ratios and 95% confidence intervals. We excluded
patients with a baseline preference for BE from the multi-
nomial analysis because so few respondents indicated it as
a test preference (6%). In the multivariable analyses,
worry about CRC was collapsed into 2 categories (never/
rarely and sometimes/most of the time/all of the time),
and stage of readiness for CRC screening was analyzed as
a continuous variable.
To evaluate concordance between baseline CRC test
preference and type of test completed, we compared each
patient’s stated preference at baseline to his or her test
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completed by 12 months. This analysis included having
an unknown preference at baseline and receiving no test
by 12 months. Baseline preferences included FOBT,
COL, SIG, BE, and unknown. Completion categories
included FOBT, COL, SIG, and no test (only 2 patients
had received BE by 12 months). Comparisons between
stated preferences and test completion were done using
chi-square analyses.
RESULTS
Description of the Sample
The mean age of study participants was 55.5 years; the
sample was composed of patients who were predominantly
African American or white, female, married, employed,
and had at least a high school education (Table 1, columns
1 and 2). Only 7% reported a family history of CRC.
Approximately half had previously been screened for CRC
and were overdue, and approximately half reported that
CRC screening had ever been recommended by a physi-
cian. Patients reported all CRC tests received; thus, the
total number of specific tests completed or recommended
exceeds the total reporting having ever been screened or
recommended for screening (Table 1 footnote). About half
stated that they preferred to make medical decisions them-
selves, whereas 40% preferred that medical decisions be
shared; only 10% preferred that a physician make medical
decisions. More than one third said they were committed
to getting tested; fewer than 10% were not thinking about
getting tested. Patients reported that they were ‘‘very confi-
dent’’ (had high self-efficacy) that they could complete
FOBT compared with the other tests. More than half of
the sample stated that they were equally likely to develop
CRC compared with others their age. The majority
reported that they rarely or never worried about CRC.
Mean knowledge scores reflected some knowledge about
CRC; mean scores were high for perceived pros and low
for perceived cons of CRC screening.
Factors Associated with Baseline CRC
Screening Preference: Univariable Analysis
Most patients stated a test preference: 34.7% indicated a
preference for FOBT, 41.1% for COL, 12.7% for SIG,
5.7% for BE, and 5.8% did not report a preference.
Factors statistically significantly associated at P<.10 with
baseline test preference for COL, SIG, or FOBT in uni-
variable analyses were family history, ever had CRC
screening with SIG, physician recommendation for any
CRC test, FOBT, and COL, preference for decision mak-
ing, stage of readiness for CRC screening, test-specific
self-efficacy for FOBT, COL or SIG, comparative per-
ceived risk, worry, and perceived pros of CRC screening
(Table 1, columns 3-6).
Factors Associated with Baseline CRC
Screening Preference: Multivariable Analysis
Table 2 shows the multivariable logistic regression results
for factors associated with preference for FOBT, COL,
or SIG, always using the less invasive test as the referent.
Because prior use of SIG was significantly associated
with preference, we also included prior use of FOBT and
COL in the multivariable models. Likewise, because phy-
sician recommendations for FOBT and COL were sig-
nificant, we included recommendation for SIG. We did
not include prior recommendation for any test (ie, ‘‘ever
received a recommendation’’) or for a nonspecific recom-
mendation because of the high correlations with
test-specific recommendations. The factors that remained
statistically significantly associated in at least 1 of the
multinomial regression models were prior use of CRC
screening with SIG, prior test-specific physician
recommendation, stage of readiness, test-specific self-
efficacy, worry about CRC, and perceived pros of CRC
screening.
Three factors were consistently and positively associ-
ated with a preference for 1 of the more invasive tests.
Patients whose physicians recommended SIG or COLwere
more likely to prefer those tests to FOBT, as were patients
who reported being more committed to screening and
those who reported being more worried about CRC.
Higher scores on the perceived pros of screening were asso-
ciated with a preference for COL over FOBT and SIG.
Greater self-efficacy for completing a specific test
was statistically significantly associated with a preference
for that test. For example, those with high self-efficacy for
FOBT were more likely to prefer FOBT to COL or SIG,
whereas those with high self-efficacy for COL were more
likely to prefer COL to FOBT or SIG. Interestingly, prior
experience with SIG was associated with a preference for
either of the other tests.
Baseline Test Preference and Test Utilization
Regardless of baseline test preference, most patients did
not get screened.18 At the 12-month follow-up, more
than 65% had no evidence in the medical record or
administrative databases of receiving any CRC screening
test; 9.7% had received FOBT, 22.3% had received COL,
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fewer than 2% had received SIG; and only 3 patients had
received BE.
The pattern of association between baseline test prefer-
ence and test completed was statistically significant (Fig. 1).
These results were driven largely by the association between
baseline preference for COL and receipt of COL. To explore
this association further, we examined preference for COL
compared with other tests in relation to screening at the 12-
month follow-up. Participants who preferred COL at base-
line were significantly more likely to complete COL by the
12-month follow-up compared with those who had a prefer-
ence for any other test (v2¼ 9.98, P¼ .002). When we re-
stricted the analysis to those who had been screened by 12
months (n¼ 448, or 34% of the sample), 51.3% (n¼ 215)
received the test that they indicated they preferred at base-
line. Of those who did not receive the test they preferred,
the majority (51.9%) received COL.
DISCUSSION
Consistent with other studies, we found that most patients
preferred COL or FOBT to the other CRC tests and that
sociodemographic characteristics were not associated with
test preferences.6-15 Collectively, these findings suggest that
offering only the options of FOBT and COL would be ac-
ceptable to most patients. Moreover, the fairly even split in
the percentage of patients who preferred those 2 tests sup-
ports the view that both tests should be offered to patients.
Figure 1. Association between baseline test preferences and
receipt of CRC screening at 12 months.
Table 2. Factors Associated with Stated Preferences for FOBT, COL, and SIG
COL Versus FOBT SIG Versus FOBT COL Versuss SIG
Family history (yes vs no) 1.08 (0.61-1.90) 0.46 (0.17-1.21) 2.36 (0.94-5.93)
Prior CRC test (yes vs no)z
FOBT 0.71 (0.45-1.12) 1.41 (0.91-2.20)
SIG 1.01 (0.93-1.09) 0.58 (0.37-0.93)* 1.73 (1.08-2.75)*
COL 1.04 (0.88-1.23) 1.01 (0.81-1.26) 1.03 (0.88-1.21)
Physician recommendation (yes vs no)z
FOBT 0.59 (0.34-1.03) 0.68 (0.32-1.47) 0.86 (0.40-1.87)
SIG 1.75 (0.87-3.56) 2.52 (1.09-5.81)* 0.69 (0.32-1.49)
COL 2.28 (1.62-3.22)y 1.78 (1.12-2.83)* 1.28 (0.84-1.96)
Preference for decision making
Physician based Ref Ref Ref
Shared 1.24 (0.74-2.09) 1.13 (0.55-2.35) 1.10 (0.54-2.22)
Patient based 0.89 (0.53-1.49) 1.25 (0.61-2.56) 0.71 (0.35-1.42)
Stage of readiness§ 1.33 (1.19-1.49)y 1.34 (1.15-1.57)y 0.99 (0.85-1.16)
Self-efficacy (very confident vs less confident)
FOBT confidence 0.48 (0.34-0.68)y 0.48 (0.30-0.76)* 1.01 (0.64-1.58)
SIG confidence 1.10 (0.75-1.62) 3.45 (2.03-5.87)y 0.32 (0.19-0.53)y
COL confidence 2.82 (1.92-4.13)y 0.70 (0.42-1.17) 4.03 (2.44-6.66)y
Comparative perceived risk
About average Ref Ref Ref
Less than average 0.83 (0.59-1.16) 0.87 (0.55-1.37) 0.95 (0.61-1.48)
More than average 1.27 (0.84-1.92) 1.01 (0.57-1.80) 1.25 (0.73-2.14)
CRC worry (sometimes/most of the time/all the time vs rarely/never) 1.96 (1.36-2.84)y 1.71 (1.05-2.78)* 1.15 (0.74-1.79)
Pros of CRC screening 1.62 (1.13-2.33)* 1.04 (0.65-1.66) 1.56 (0.98-2.48)
COL, colonoscopy; CRC, colorectal cancer; FOBT, fecal occult blood test; SIG, sigmoidoscopy.
*P<.05;
yP<.001.
zRespondents could report having had more than 1 test and/or having had recommendations for more than 1 test.
§Rate ratio applies to each 1-step increase in stage of change, that is, for each increase in stage, there was a 33% increase for COL versus FOBT and a 34%
increase for SIG versus FOBT.
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To our knowledge, ours is one of the few studies to
examine psychosocial factors associated with test prefer-
ence. Like Powell et al,12 we found an association between
greater self-efficacy for screening with COL and a prefer-
ence for that test. However, unlike Powell et al, we also
found that greater self-efficacy for FOBT and SIG were
associated with a preference for those tests. Powell et al
also found that scoring high on the salience or importance
of screening was associated with a preference for COL
over other options, and we found that higher scores on the
pros of screening were associated with a preference for
COL. In our study, patients at a higher stage of readiness
to get tested also preferred SIG or COL to other options.
It may be that as patients learn about the benefits of
screening and its importance in preventing CRC, they are
more likely to commit to getting screened and to choose a
test that, although invasive, can prevent CRC. Increasing
support for COL by primary care physicians compared
with other CRC screening tests may also contribute to
patient preference for this option.27 In contrast, those
least interested in getting screened were more likely to
choose FOBT, a test that requires less planning and prepa-
ration, is more convenient to do, and is less invasive than
SIG or COL.
Like 2 other studies,11,12 we found an association
between the test that a patient said the physician recom-
mended and preference for that test. However, 1 study8
found that one third of the patients in the sample said
they would adhere to their choice even if their physician
recommended an alternative test. Our finding that only
10% of the patients in our sample favored having a physi-
cian make their medical decisions supports the view that
although patients may value the opinions of their physi-
cians, they want to have a voice in making medical deci-
sions. These findings underscore the need for physicians
to be aware of and consider patients’ preferences when
making recommendations. Our findings also support
educating patients about the importance of advocating for
their own preferences in visits with their physicians.
With the exception of SIG, we found no association
and no consistent pattern in the odds ratios between prior
screening with a specific test and preference for future
screening with that test. In fact, counter to what might be
expected, prior experience with SIG was associated with a
preference for either of the other tests, suggesting that hav-
ing SIG did not reinforce a commitment to future screen-
ing with SIG. Likewise, findings from other studies also
have been inconsistent with respect to the association
between prior screening and preference, with some studies
finding a positive association,8-10,16 some finding no asso-
ciation,6,11,13 and some finding different patterns depend-
ing on the test.7,12 The lack of association between prior
screening with COL or FOBT and a preference for those
tests together with the positive association between physi-
cian recommendation and a preference for the recom-
mended test suggests that prior screeners may be open to
considering other test options. However, our finding that
patients preferred the test that they were more confident
they could complete suggests that physicians need to take
patients’ perceived confidence into consideration when
they make a test recommendation.
Although consistent with other studies,14,15,17 our
potentially most concerning finding was the lack of associ-
ation between patients’ stated test preference at baseline
and the type of test they received (if any). This discrepancy
could contribute to the overall low uptake of screening we
observed, and future studies should investigate whether
patients who do not feel that their test preferences are sup-
ported by their physicians are less likely to be adherent to
CRC screening recommendations and guidelines. Recent
studies have found that the extent of informed decision
making for CRC screening during primary care visits is
minimal.28,29 Recent studies, including 1 conducted with
a subsample of participants in this intervention trial, also
have documented that primary care physicians tend to
recommend COL above other screening tests regardless of
a patient’s expressed preference.27,29,30 If COL continues
to be the most commonly recommended CRC screening
test in primary care,27,29,30 educational programs that
emphasize the benefits of COL may increase patients’ re-
ceptivity to it, particularly if they are supported by a dis-
cussion with the provider and by systems that facilitate
scheduling and completing the test.
Our findings need to be interpreted in the context of
several limitations. The study setting was a large multispe-
cialty group practice where patients have relatively equal
access to all CRC tests; therefore, our results may not gen-
eralize to settings without access to all test options. In
addition, the study design used to assess associations
between preference and psychosocial and other factors
was cross-sectional; therefore, inferences about the direc-
tion of influence cannot be made. Finally, test preference
was only assessed at baseline, and it is possible that it
changed after patients met with their physicians. If this
were the case, it could explain why patients who preferred
COL were more likely to be screened compared with
those who preferred other tests and why patients who pre-
ferred FOBT received COL.
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CONCLUSIONS
Patients at a higher stage of readiness for CRC screening,
who reported more pros of screening, and who expressed
more worry about CRC preferred one of the more inva-
sive tests. Although, in general, patients preferred the test
their physicians recommended, lack of concordance
between patient preference and test completed suggests
that patients’ preferences are not well incorporated into
screening discussions and test decisions. Ensuring that
patients understand the benefits of screening and that
they receive information about what each test entails may
increase their self-efficacy and make it more likely that
they will complete the test they choose.
Practice Implications
Primary care physicians need to be aware that patients’ pref-
erences for CRC screening tests differ. Assessing and
acknowledging these preferences when making CRC screen-
ing recommendations could positively affect patient adher-
ence. In addition, educating patients about the benefits of
screening and providing support for completing the test they
choose may make patients more receptive to CRC screening.
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